Historial de ingresos, beneficios y flujo de caja según los estados financieros oficiales.
Neuland Laboratories Limited engages in the manufacture and sale of active pharmaceutical ingredients (APIs) in India, Europe, the United States, and internationally. It also provides custom manufacturing solutions, generic drug substances, as well as peptide APIs and synthesis services. The company serves generic companies, regional and domestic pharmaceutical manufacturers, distributors, and other pharmaceutical and biotechnology companies. Neuland Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
Ver gráficos interactivos y estados completos →
| Cuenta de resultados | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 |
|---|---|---|---|---|
| Ingresos totales | ₹19.3B | ₹14.3B | ₹15.2B | ₹11.6B |
| Beneficio bruto | ₹9.8B | ₹6.8B | ₹7.8B | ₹5.5B |
| Ingresos operativos (EBIT) | ₹4.9B | ₹2.7B | ₹4.1B | ₹2.3B |
| Ingresos netos | ₹3.6B | ₹2.6B | ₹3.0B | ₹1.6B |
Fuente: informes públicos de la empresa (SEC). Verifique en SEC EDGAR antes de confiar en cualquier cifra.
Balances, flujos de caja, datos trimestrales y ratios completos en el visor interactivo de NEULANDLAB. /companies/us/NEULANDLAB
La información de este sitio es solo educativa e informativa; no constituye asesoramiento de inversión. No se publican precios objetivo ni recomendaciones.
About TickerBase · Data methodology & sources · Privacy · Terms